Search
Insilico Medicine (03696) experienced a more than 4% uptick in its share price during the morning trading session. At the time of reporting, the stock had surged by 4.56%, trading at HK$63 per share, with a trading volume amounting to HK$7.5017 million. Insilico Medicine has disclosed that the MEN2501 project, which it licensed to the Menarini Group, has successfully completed the dosing of the first patient in a Phase I clinical trial. This achievement has triggered a milestone payment of roughly HK$39 million to Insilico Medicine. MEN2501 is a small-molecule inhibitor specifically designed to target the kinesin protein KIF18A. In a prior arrangement, Insilico Medicine had out-licensed this project to the Menarini Group, with the total value of the cooperation reaching approximately HK$4.29 billion.
-
C114 Communication Network -
Communication Home
